 |
 |
  Short News
10.24.2012 New TRPML1 agonist.
Screening research conducted by University of Michigan showed 2 hits with compounds from Princeton BioMolecular drug-like set of Mucolipin transient receptor potential channel agonist. 07.04.2012 New LabPrinceton Biomolecular Research has recently opened up a new state of the art lab providing custom synthesis... |
Princeton BioMolecular Research
Princeton BioMolecular Research is a privately held company established in 1998. We design unique small molecules and develop advanced tools for drug discovery, enabling new generations of chemical entities. Currently we are engaged in extensive research into several different activities which includes; Central Nervous System Diseases (Antiparkinsonian, Alzheimer's disease treatment, Cognition disorders treatment). Antineoplastic (myeloid leukemia, lymphocytic ,leukemia) and Antiviral (Rhinovirus, Arbovirus).
we accept all major credit cards  |
 Discovery Outsource      |
 |
|
 |